Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
-3.66% $0.395
Last updated: 3 jul 2022 - 20:16
TimeZone: America/New_York
FUNDAMENTALS | |
---|---|
MarketCap: | 38.50 mill |
EPS: | -0.165 |
P/E: | 0.000 |
Earnings Date: | Aug 15, 2022 |
SharesOutstanding: | 97.47 mill |
Avg Daily Volume: | 0.210 mill |
RATING 2022-07-01 |
---|
B+ |
Neutral |
RATINGDETAILS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | ||||||
Asset | ||||||
Debt |
True Range Average |
---|
+/- $0.0340 ( +/- 8.61%) Range: 0.361 - 0.429 |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-08-20 | Pfenniger Richard C Jr | Buy | 40 000 | Common Stock |
2021-07-16 | Martin James Joseph | Buy | 250 000 | Stock Options (Right to Buy) |
2021-07-16 | Frost Phillip Md Et Al | Buy | 65 000 | Stock Options (Right to Buy) |
2021-07-16 | Pfenniger Richard C Jr | Buy | 50 000 | Stock Options (Right to Buy) |
2021-07-16 | Kornberg Roger D. | Buy | 65 000 | Stock Options (Right to Buy) |
INSIDER POWER |
---|
18.76 |
Last 92 transactions |
Buy: 453 925 162 | Sell: 59 808 344 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.395 (-3.66% ) |
Volume | 0.0477 mill |
Avg. Vol. | 0.210 mill |
% of Avg. Vol | 22.67 % |
Signal 1: | |
Signal 2: |
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. The company is headquartered in Bothell, Washington and currently employs 10 full-time employees. The firm focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The firm focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C, influenza and norovirus. The firm uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The firm is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.